VYNE Therapeutics (VYNE) Operating Expenses (2016 - 2026)

VYNE Therapeutics' Operating Expenses history runs 11 years deep, the most recent figure standing at $3.9 million for Q1 2026.

• Quarterly Operating Expenses fell 58.48% year-over-year to $3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.9 million (down 54.6% YoY) and the FY2025 annual result came in at $30.3 million, down 31.31% from the prior year.
• Operating Expenses was $3.9 million for Q1 2026 at VYNE Therapeutics, down from $7.6 million in the prior quarter.
• Across five years, Operating Expenses topped out at $13.2 million in Q3 2024 and bottomed at $3.9 million in Q1 2026.
• A 5-year average of $8.6 million and a median of $8.4 million in 2022 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2024 — Operating Expenses soared 108.13% — and 2026, when it sank 58.48%.
• VYNE Therapeutics' Operating Expenses stood at $8.0 million in 2022, then fell by 13.54% to $6.9 million in 2023, then jumped by 86.07% to $12.9 million in 2024, then plunged by 40.79% to $7.6 million in 2025, then sank by 48.73% to $3.9 million in 2026.
• Business Quant data shows VYNE's Operating Expenses at $3.9 million in Q1 2026, $7.6 million in Q2 2025, and $9.4 million in Q1 2025.